Lancet Infectious Diseases Review Time

The official Lancet materials make the journal's identity very explicit. It is framed around clinical, public-health, and global-health knowledge in infectious diseases.

They tell you:

• the journal sees itself as world-leading in infectious diseases
• broad consequence is central to scope
• the readership and citation position are elite

They do not tell you:

• a public median time to first decision
• a public median time to acceptance
• how long internal editorial debate can take before a no or transfer recommendation

That means the real timing picture comes from combining:

• official journal positioning, which explains why the triage bar is so strict
• author-reported timing, which shows how long the editorial process can take when the paper is plausible but not clearly decisive

For this journal, timing is mostly a byproduct of how broad the paper's consequence really is.

That is why some authors experience the journal as "fast" and others experience it as "slow." Both impressions can be correct depending on fit.

This journal is not just looking for strong infectious-disease science. It is looking for work that travels broadly across clinical or global-infectious-disease decision making.

Papers tend to get filtered when they are:

• strong but regionally narrow without broader policy consequence
• mechanistically interesting yet clinically premature
• pathogen-specific stories without field-wide significance
• good infectious-disease work better suited to CID, JID, or specialist venues
• translational in tone but not in immediate implication

That is why a manuscript can be impressive and still be a quick no here.

The slower cases are usually the ones that look plausible enough for real editorial discussion.

The common causes are:

• internal debate over whether the study is broad enough for the journal
• uncertainty about how globally or clinically actionable the result is
• reviewer selection across clinical, epidemiologic, and policy angles
• revision demands that push the paper to clarify practice or public-health consequence
• transfer consideration when the science is strong but not right for the exact title

When Lancet Infectious Diseases feels slow, it is often because the paper is caught between being good and being journal-defining enough.

Lancet Infectious Diseases is down from 36.4 in 2023 to 31.0 in 2024, continuing the normalization after the extraordinary pandemic-era citation spike.

For review time, the useful implication is that the journal still occupies a dominant position and can keep filtering hard for broad consequence rather than publication volume.

Even useful author-reported timing hides the real determinants:

• a month-long desk outcome can still mean the paper never really had the right scope
• fast review is irrelevant if the manuscript is filtered on consequence
• the journal cares as much about policy or practice meaning as about scientific rigor
• timing pain is often caused by trying to make a specialist paper compete in a flagship lane

So the clock matters, but the editorial question matters more.

In our pre-submission review work, the biggest timing mistake is assuming that any excellent infectious-disease paper should first test this journal because the downside is "just a desk rejection."

That can still be expensive.

The papers that move best here usually have:

• a global or field-wide infectious-disease consequence visible early
• a result that changes interpretation, practice, stewardship, or policy
• a title and abstract that do not need specialist context to sound important
• enough maturity that the broad-readership case is self-evident

Those traits make the journal's screening logic work in the paper's favor.

For Lancet Infectious Diseases, timing matters less than broad infectious-disease consequence. The better question is whether the manuscript already behaves like a flagship infectious-diseases paper.

That is why the better next reads are:

• Lancet Infectious Diseases journal profile
• Lancet Infectious Diseases submission guide
• Lancet Infectious Diseases formatting requirements
• Is Lancet Infectious Diseases a good journal?

A Lancet Infectious Diseases fit check is usually more valuable than trying to optimize around the desk clock alone.

Lancet Infectious Diseases review time is a function of selectivity first and logistics second. Obvious mismatches can be rejected in days. Borderline but credible papers can spend longer in editorial sorting before the journal decides whether they deserve review. If the paper really changes broad infectious-disease thinking, that process can be worth it. If not, the timing pain is mostly a signal that another venue was the better home.